Updates in Surgery

, Volume 66, Issue 2, pp 109–113

The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse

  • E. Saladino
  • F. Fleres
  • S. Irato
  • C. Famulari
  • A. Macrì
Review Article

DOI: 10.1007/s13304-013-0229-9

Cite this article as:
Saladino, E., Fleres, F., Irato, S. et al. Updates Surg (2014) 66: 109. doi:10.1007/s13304-013-0229-9

Abstract

Nowadays the standard clinical management for advanced epithelial ovarian cancer is constituted by primary cytoreductive surgery associated to adjuvant systemic chemotherapy. Even if this first-line chemotherapy shows a high rate of complete responses, the disease recurrences occur especially in stage-III patients. Actually an option for this subset of patients is represented by secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy that represents a promising therapy, having shown positive results in terms of median overall survival, progression free survival and overall survival. However, a much more research is still required especially by prospective randomised trials to improve outcomes in recurrent ovarian cancer.

Keywords

CRSHIPECEpithelial ovarian cancerRecurrence

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • E. Saladino
    • 1
  • F. Fleres
    • 1
  • S. Irato
    • 2
  • C. Famulari
    • 1
  • A. Macrì
    • 1
  1. 1.General Surgery Unit, Department of Human PathologyUniversity of MessinaMessinaItaly
  2. 2.Gynecological and Obstetrical Unit, Department of Sciences and Reproductive MedicineUniversity of MessinaMessinaItaly